“The choice between CRT with (CRT-D) or without (CRT-P) a defibrillator remains a contentious issue,” said Professor Jean-Yves Le Heuzey, cardiologist at Georges Pompidou Hospital, René Descartes University in Paris, France. “No randomised clinical trial has been conducted to guide this choice.”
Patients with congestive heart failure are at high risk of dying from sudden cardiac death. Over the last decade, CRT and implantable cardioverter defibrillators (ICDs) have markedly improved prognosis. Guidelines do not make firm recommendations on the choice of CRT-P versus CRT-D, stating that there is insufficient evidence from randomised controlled trials to show that CRT-D would additionally improve survival compared to CRT-P.2 This has left room for physician discretion and resulted in wide variation in worldwide implantation rates. For instance, the proportion of CRT implantations which are CRT-D reaches more than 90% in the US whereas it is lesser across Europe.
“Whether such a high rate of CRT-D use over CRT-P is justified is an important question to answer in terms of significant costs and device-related complications,” said Professor Le Heuzey. “ICD lead failures, inappropriate shocks and risk of infection are real problems with impacts on quality of life and possibly survival. But the ideal way to answer this question, a randomised controlled trial directly comparing CRT-P to CRT-D, would have to be large, expensive and is unlikely to ever be conducted.”
The CeRtiTuDe study evaluated the characteristics of CRT-P versus CRT-D patients in a real-world scenario and analysed to what extent CRT-P patients would have benefited from the presence of a back-up defibrillator. It was a multicentre prospective follow-up cohort study that enrolled a total of 1 705 consecutive patients implanted with a CRT (CRT-P 535; CRT-D 1 170) between 2008 and 2010 in France. Adjudication for causes of death was conducted at two years follow up.
Patients with CRT-P compared to CRT-D (Figure 1) were older (75.9 vs 65.6 years, p<0.0001), less often male (69.5 vs 80.8%, p<0.0001), more symptomatic (proportion of NYHA class III/IV, 88 vs 80%, p=0.002), with less coronary artery disease (40.7 vs 49.3%, p=0.003), wider QRS (161 ± 29 vs 155 ± 26 msec, p=0.002), more atrial fibrillation (38.7 vs 22.1%, p<0.0001) and more comorbidities (≥ 2 comorbidities 16.9 vs 12.9 %, p=0.04).
At two year follow up 270 patients had died, giving an annual overall mortality rate of 77.9 per 1 000. The crude mortality rate among CRT-P patients was double compared to CRT-D (relative risk [RR]=1.96, 95% confidence interval[CI]=1.51-2.66). “By cause-of-death analysis, a large proportion of the excess mortality among CRT-P subjects was related to an increase of non-sudden death,” said Professor Le Heuzey. “This could indicate that this excess mortality is due to heart failure and non cardiovascular events.”
He concluded: “Our findings suggest that patients selected for CRT-P in routine clinical practice would not benefit from the addition of a defibrillator. This indicates that CRT-D rates could be reduced, with consequent decreases in costs and device-related complications.”
Figure 1: Clinical profile of CRT-P (red) and CRT-D (blue) recipients
DCM=(non ischaemic) dilated cardiomyopathy; AF=atrial fibrillation
1Professor Le Heuzey will present the abstract ‘CRT-P or CRT-D? The CeRtiTuDe Cohort Study’ at 09:00 during:
• Registry II – Interventions / Acute cardiovascular care on Tuesday 1 September at 08:30 in St James Park (The Hub)
22013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal. 2013;34:2281–2329.
Notes to editor
SOURCES OF FUNDING: The study was sponsored by the French Society of Cardiology with grants from Biotronik, Boston Scientific, Medtronic, Saint Jude Medical and Sorin.
ESC Press Office
For background information or assistance, please contact the ESC Press Office.
For independent comment on site or interviews, please contact the ESC spokesperson coordinator: +44 7785 467 947
About the European Society of Cardiology
The European Society of Cardiology (ESC) represents more than 90 000 cardiology professionals across Europe and worldwide. Its mission is to reduce the burden of cardiovascular disease in Europe.
About ESC Congress 2015
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2015 takes place 29 August to 2 September at ExCel London in London, UK. Access the scientific programme. More information is available from the ESC Press Office at email@example.com.
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.
This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2015. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.